SMAD3 and neoplasm: miR‐92b, which has various functions, was reported to be induced by PPAR‐γ and to inhibit Axl expression, in turn reducing the expression of TGF‐β1 and downstream genes in keloid fibroblasts and attenuating oncogenicity effects by directly targeting Smad3, RAB23 and Gabra3 in nasopharyngeal cancer, oesophageal squamous cell carcinoma and pancreatic cancer.10, 11, 12, 13 These studies indicated that miR‐92b might act as a tumour suppressor in some human cancers; however, miR‐92b also might have different functions in different tumours.